Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
https://www.zacks.com/stock/news/2237558/emergent-ebs-down-16-on-q4-earnings-miss-tops-on-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-2237558
Mar 07, 2024 - Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
0
Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/03/06/emergent-biosolutions-ebs-q4-2023-earnings-call-tr/?source=iedfolrf0000001
Mar 06, 2024 - EBS earnings call for the period ending December 31, 2023.
0
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2236966/emergent-biosolutions-ebs-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2236966
Mar 06, 2024 - Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -133.33% and 11.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-235-8m-dod-contract-for-anthrax-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209718
Jan 12, 2024 - Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
0
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2196220/emergent-biosolutions-ebs-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2196220
Dec 11, 2023 - Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -1,100% and 5.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Pages: 1
Page 1